From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?
暂无分享,去创建一个
Patrick W Serruys | Yoshinobu Onuma | Hector M Garcia-Garcia | P. Serruys | H. Garcia-Garcia | Y. Onuma
[1] J. Ormiston,et al. Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. , 1997, Circulation.
[2] P. Hunold,et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. , 2005, Circulation.
[3] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.
[4] P. Serruys,et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. , 2010, European heart journal.
[5] D. Teupser,et al. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.
[6] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[7] Orchard Tj. Letter: Mobile coronary care. , 1974 .
[8] P. Serruys,et al. Heme Oxygenase 1 Determines Atherosclerotic Lesion Progression Into a Vulnerable Plaque , 2009, Circulation.
[9] Raimund Erbel,et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.
[10] H. Uehata,et al. FRS-177 Four-year Follow-up of the Biodegradable Stent (IGAKI-TAMAI Stent)(Percutaneous Coronary Intervention (IHD) : FRS21)(Featured Research Session (English)) , 2004 .
[11] F Joffre,et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.
[12] Peter Jüni,et al. Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis , 2009, Circulation.
[13] J C Greenfield,et al. Interventional cardiac catheterization at Duke Medical Center. , 1988, The American journal of cardiology.
[14] H. Uehata,et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.
[15] Nitzan Resnick,et al. Fluid shear stress and the vascular endothelium: for better and for worse. , 2003, Progress in biophysics and molecular biology.
[16] Bernard Chevalier,et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.
[17] P D Verdouw,et al. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. , 1992, Journal of interventional cardiology.
[18] R. Virmani,et al. Ultrasonic and pathological evidence of a neo-intimal plaque rupture in patients with bare metal stents. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[19] S. Glagov,et al. Mechanical determinants of plaque modeling, remodeling and disruption. , 1997, Atherosclerosis.
[20] E J Topol,et al. Artery size, neointima, and remodeling: time for some standards. , 1998, Journal of the American College of Cardiology.
[21] P. Serruys,et al. First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era? , 2009, Nature Reviews Cardiology.
[22] P. Serruys,et al. The role of shear stress in the generation of rupture-prone vulnerable plaques , 2005, Nature Clinical Practice Cardiovascular Medicine.
[23] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[24] R. Virmani,et al. Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.
[25] R A Schatz,et al. Clinical experience with the Palmaz-Schatz coronary stent. , 1991, Journal of the American College of Cardiology.
[26] Julio C. Palmaz,et al. Clinical Experience With the Palmaz‐Schatz Coronary Stent: Initial Results of a Multicenter Study , 1991, Circulation.
[27] Masataka Nakano,et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.
[28] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[29] A. Tedgui,et al. Cellular mechanics and gene expression in blood vessels. , 2003, Journal of biomechanics.
[30] J. Roelandt,et al. Images in Cardiovascular Medicine , 2000 .
[31] P. Serruys,et al. Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[32] Patrick W Serruys,et al. Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization? , 2011, Circulation.
[33] P. Serruys,et al. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus‐eluting device during the bioabsorption process , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[34] J. Davies,et al. Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.
[35] H. Morita,et al. Evaluation of the usefulness of recording the ECG in the 3rd intercostal space and prevalence of Brugada-type ECG in accordance with recently established electrocardiographic criteria. , 2004, Circulation journal : official journal of the Japanese Circulation Society.
[36] M D McKee,et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. , 1999, Circulation research.
[37] Bernard Chevalier,et al. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.
[38] Erhan Babalik,et al. Fracture of popliteal artery stents. , 2003, Circulation journal : official journal of the Japanese Circulation Society.
[39] M. Slepian. Polymeric endoluminal gel paving: therapeutic hydrogel barriers and sustained drug delivery depots for local arterial wall biomanipulation. , 1996, Seminars in interventional cardiology : SIIC.
[40] Bernard Chevalier,et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. , 2010, JACC. Cardiovascular interventions.
[41] P. Serruys,et al. Three-dimensional visualization of intracoronary thrombus during stent implantation using the second generation, Fourier domain optical coherence tomography , 2009, European heart journal.
[42] A Gruntzig,et al. Transluminal dilatation of coronary-artery stenosis. , 1978, Lancet.
[44] Patrick W Serruys,et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. , 2011, European heart journal.
[45] Attila Thury,et al. Images in cardiovascular medicine. Focal in-stent restenosis near step-up: roles of low and oscillating shear stress? , 2002, Circulation.
[46] Muzaffer Degertekin,et al. True Three-Dimensional Reconstructed Images Showing Lumen Enlargement After Sirolimus-Eluting Stent Implantation , 2002 .
[47] A. Tzafriri,et al. Strut Position, Blood Flow, and Drug Deposition: Implications for Single and Overlapping Drug-Eluting Stents , 2005, Circulation.
[48] B Meier,et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.
[49] P. Serruys,et al. Coronary stents: current status. , 2010, Journal of the American College of Cardiology.
[50] G. D. De Meyer,et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. , 2007, Journal of the American College of Cardiology.
[51] Ron Waksman,et al. Biodegradable stents: they do their job and disappear. , 2006, The Journal of invasive cardiology.
[52] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[53] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[54] R. Virmani,et al. The bioabsorption process: tissue and cellular mechanisms and outcomes. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[55] D Glogar,et al. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. , 2000, Journal of the American College of Cardiology.
[56] P. Serruys,et al. The bailout stent. Is a friend in need always a friend indeed? , 1993, Circulation.
[57] J J Wentzel,et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. , 2000, Journal of biomechanics.
[58] Frits Mastik,et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.
[59] Patrick W Serruys,et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.
[60] Renu Virmani,et al. Is pathologic intimal thickening the key to understanding early plaque progression in human atherosclerotic disease? , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[61] Janita F. J. Vos,et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. , 2001, European heart journal.
[62] Jeffrey J. Popma,et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001, Circulation.
[63] P. Serruys,et al. Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries. , 2003, The American journal of cardiology.
[64] Larry S. Dean,et al. Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.
[65] John A Ormiston,et al. First‐in‐human implantation of a fully bioabsorbable drug‐eluting stent: The BVS poly‐L‐lactic acid everolimus‐eluting coronary stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[66] L. Skovgaard,et al. Strut apposition after coronary stent implantation visualised with optical coherence tomography. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[67] P. Serruys,et al. Rapamycin modulates the eNOS vs. shear stress relationship. , 2008, Cardiovascular research.
[68] J. Tasto,et al. Bioabsorbable implants in orthopaedics: new developments and clinical applications. , 2001, The Journal of the American Academy of Orthopaedic Surgeons.
[69] G. D. De Meyer,et al. Everolimus-Induced mTOR Inhibition Selectively Depletes Macrophages in Atherosclerotic Plaques by Autophagy , 2007, Autophagy.